Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol.

Alberto Bongiovanni, Chiara Liverani, Sara Pusceddu, Silvana Leo, Giovanni Di Meglio, Stefano Tamberi, Daniele Santini, Fabio Gelsomino, Francesca Pucci, Rossana Berardi, Ivan Lolli, Francesca Bergamo, Sergio Ricci, Flavia Foca, Stefano Severi, Toni Ibrahim, Nicola Silvestris

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol.'. Together they form a unique fingerprint.

Medicine & Life Sciences